Verve Therapeutics
CAMBRIDGE, MA · Founded 2018 · CIK 0001840574 · Biotech · Acquired
Base editing therapeutics that permanently reduce LDL cholesterol by targeting PCSK9 gene
vervetx.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $94M
- 1 Form D · Jan 2021
- 69 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 9 granted · 31 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20202021
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $93,999,993 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2836 | Arcutis Biotherapeutics, Inc. | — | $94M |
| 2837 | OMNI BIO PHARMACEUTICAL, INC. | — | $28M |
| 2838 | ReAlta Life Sciences, Inc. | — | $94M |
| 2839 | Verve Therapeutics | — | $94M |
| 2840 | Scorpion Therapeutics | — | $297M |
| 2841 | VASCULAR BIOSCIENCES, INC. | — | — |
| 2842 | EXPRESSION THERAPEUTICS, LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Burt AdelmanDirector
- Andrew AsheExecutive Officer
- Andrew BellingerExecutive Officer
- John EvansDirector
- Sekar KathiresanDirector · Executive Officer
- Anthony PhilippakisDirector
- Krishna YeshwantDirector
Patents
- Compositions And Methods For Targeted Rna Deliveryapplication
- Chemically Modified Guide Rnas For Genome Editing With CAS12Bgranted
- Compositions And Methods For Targeted Rna Deliverygranted
- Lipid Formulations For Gene Editingapplication
- Lipid Formulations For Gene Editinggranted
- Compositions And Methods For Capping Rnasapplication
- Base Editing Of ANGPTL3 And Methods Of Using Same For Treatment Of Diseaseapplication
- Compositions And Methods For Targeted Rna Deliverygranted
- Compositions And Methods For Capping Rnasgranted
- Compositions And Methods For Capping Rnasapplication
- Base Editing Of PCSK9 And Methods Of Using Same For Treatment Of Diseaseapplication
- Gene Editing Of PCSK9 Or ANGPTL3 And Compositions And Methods Of Using Same For Treatment Of Diseaseapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.